Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

PURPOSE: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. This phase III trial compared tivozanib with sorafenib as initial targeted therapy in patients with metastatic renal cell carcinoma (RCC). PATIENTS AND METHOD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Motzer, Robert J., Nosov, Dmitry, Eisen, Timothy, Bondarenko, Igor, Lesovoy, Vladimir, Lipatov, Oleg, Tomczak, Piotr, Lyulko, Oleksiy, Alyasova, Anna, Harza, Mihai, Kogan, Mikhail, Alekseev, Boris Y., Sternberg, Cora N., Szczylik, Cezary, Cella, David, Ivanescu, Cristina, Krivoshik, Andrew, Strahs, Andrew, Esteves, Brooke, Berkenblit, Anna, Hutson, Thomas E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569677/
https://ncbi.nlm.nih.gov/pubmed/24019545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.4940
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados